Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,22749591,flow rate,"The mobile phase consisted of 70% acetonitrile and 30% water with 0.1% formic acid, pumped at a flow rate of 0.25 ml/min.",Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749591/),[ml] / [min],0.25,5991,DB06589,Pazopanib
,22749591,Analysis time,Analysis time was 3.5 min per run and both the analyte and IS eluted within 1.8-2.0 min.,Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749591/),[min] / [run],3.5,5992,DB06589,Pazopanib
,22749591,precursor,The precursor to product ions (Q1→Q3) selected for pazopanib and internal standard during quantitative optimization were (m/z) 438.1→357.2 and 475.0→112.2 respectively.,Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749591/),,438.1,5993,DB06589,Pazopanib
,22749591,m/z,The precursor to product ions (Q1→Q3) selected for pazopanib and internal standard during quantitative optimization were (m/z) 438.1→357.2 and 475.0→112.2 respectively.,Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749591/),,438.1,5994,DB06589,Pazopanib
,22749591,m/z,The precursor to product ions (Q1→Q3) selected for pazopanib and internal standard during quantitative optimization were (m/z) 438.1→357.2 and 475.0→112.2 respectively.,Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749591/),,357.2,5995,DB06589,Pazopanib
,22749591,m/z,The precursor to product ions (Q1→Q3) selected for pazopanib and internal standard during quantitative optimization were (m/z) 438.1→357.2 and 475.0→112.2 respectively.,Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749591/),,475.0,5996,DB06589,Pazopanib
,22749591,m/z,The precursor to product ions (Q1→Q3) selected for pazopanib and internal standard during quantitative optimization were (m/z) 438.1→357.2 and 475.0→112.2 respectively.,Determination of pazopanib (GW-786034) in mouse plasma and brain tissue by liquid chromatography-tandem mass spectrometry (LC/MS-MS). ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22749591/),,112.2,5997,DB06589,Pazopanib
,31186313,progression-free survival,"Thirteen patients were enrolled in the DTC cohort; OR was 33% (95% confidence interval, 9.9, 65.1%) and median progression-free survival was 10.7 months.",A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31186313/),month,10,9163,DB06589,Pazopanib
,21827214,Absolute bioavailability,Absolute bioavailability in humans has been investigated only for imatinib (almost 100%) and pazopanib (14-39%; n = 3).,"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,100,12901,DB06589,Pazopanib
,21827214,Absolute bioavailability,Absolute bioavailability in humans has been investigated only for imatinib (almost 100%) and pazopanib (14-39%; n = 3).,"Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,14-39,12902,DB06589,Pazopanib
,21827214,absolute bioavailability,"Quite low absolute bioavailability under fasted conditions is assumed for nilotinib (31%), sorafenib (50%) and sunitinib (50%).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,31,12903,DB06589,Pazopanib
,21827214,absolute bioavailability,"Quite low absolute bioavailability under fasted conditions is assumed for nilotinib (31%), sorafenib (50%) and sunitinib (50%).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),%,50,12904,DB06589,Pazopanib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,1.5-2.5,12905,DB06589,Pazopanib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,2.0,12906,DB06589,Pazopanib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,3,12907,DB06589,Pazopanib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,1.2-4.5,12908,DB06589,Pazopanib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,5.7-6.4,12909,DB06589,Pazopanib
,21827214,accumulation ratios,"At steady state, the accumulation ratios are 1.5-2.5 (unchanged imatinib), 2.0 (nilotinib once-daily dosing), 3.4 (nilotinib twice-daily dosing), 1.2-4.5 (pazopanib), 5.7-6.4 (sorafenib) and 3.0-4.5 (sunitinib).","Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21827214/),,3.0-4.5,12910,DB06589,Pazopanib
,21712450,clinical benefit rate,The clinical benefit rate was 54.5% (95% CI: 38.0-70.2).,A Phase II study of pazopanib in Asian patients with recurrent/metastatic nasopharyngeal carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21712450/),%,54.,41635,DB06589,Pazopanib
>,25349968,Cτ threshold,"Cτ threshold of >20.5 μg ml(-1) was associated with improved efficacy (PFS, P<0.004; tumour shrinkage, P<0.001), but there was no appreciable benefit in absolute PFS or tumour shrinkage from Cτ >20.5 μg ml(-1).",Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25349968/),[μg] / [ml],20.5,55964,DB06589,Pazopanib
>,25349968,Cτ,"Cτ threshold of >20.5 μg ml(-1) was associated with improved efficacy (PFS, P<0.004; tumour shrinkage, P<0.001), but there was no appreciable benefit in absolute PFS or tumour shrinkage from Cτ >20.5 μg ml(-1).",Relationships between pazopanib exposure and clinical safety and efficacy in patients with advanced renal cell carcinoma. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25349968/),[μg] / [ml],20.5,55965,DB06589,Pazopanib
,26779916,Maximum tolerated dose,Maximum tolerated dose was 400 mg of pazopanib and 75 mg/m(2) of cisplatin.,Pharmacokinetic interaction between pazopanib and cisplatin regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779916/),mg,400,56757,DB06589,Pazopanib
,26779916,Maximum tolerated dose,Maximum tolerated dose was 400 mg of pazopanib and 75 mg/m(2) of cisplatin.,Pharmacokinetic interaction between pazopanib and cisplatin regimen. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779916/),mg,75,56758,DB06589,Pazopanib
,26779916,clearance,Mean (CV % for inter-individual variability) cisplatin clearance was 10.3 L/h (33.2 %) and appeared not to be influenced by pazopanib.,Pharmacokinetic interaction between pazopanib and cisplatin regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779916/),[l] / [h],10.3,56759,DB06589,Pazopanib
,26779916,clearance,"Mean (CV %) of oral pazopanib clearance was 0.66 L/h (55 %) at Day 0 (before cisplatin administration), 24.8 % lower at Day 1 and 32.9 % lower at Day 2.",Pharmacokinetic interaction between pazopanib and cisplatin regimen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26779916/),[l] / [h],0.66,56760,DB06589,Pazopanib
,24643910,MM constant (Km),"The MM constant (Km) values of OATP-1B1 for nilotinib and vandetanib are 10.14±1.91 and 2.72±0.25 μM, respectively, and Vmax values of OATP-1B1 for nilotinib and vandetanib were 6.95±0.47 and 75.95±1.99 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),μM,10.14,58786,DB06589,Pazopanib
,24643910,MM constant (Km),"The MM constant (Km) values of OATP-1B1 for nilotinib and vandetanib are 10.14±1.91 and 2.72±0.25 μM, respectively, and Vmax values of OATP-1B1 for nilotinib and vandetanib were 6.95±0.47 and 75.95±1.99 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),μM,2.72,58787,DB06589,Pazopanib
,24643910,Vmax,"The MM constant (Km) values of OATP-1B1 for nilotinib and vandetanib are 10.14±1.91 and 2.72±0.25 μM, respectively, and Vmax values of OATP-1B1 for nilotinib and vandetanib were 6.95±0.47 and 75.95±1.99 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),[nM] / [·mg·min],6.95,58788,DB06589,Pazopanib
,24643910,Vmax,"The MM constant (Km) values of OATP-1B1 for nilotinib and vandetanib are 10.14±1.91 and 2.72±0.25 μM, respectively, and Vmax values of OATP-1B1 for nilotinib and vandetanib were 6.95±0.47 and 75.95±1.99 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),[nM] / [·mg·min],75.95,58789,DB06589,Pazopanib
,24643910,Km,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),μM,12.18,58790,DB06589,Pazopanib
,24643910,Km,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),μM,7.84,58791,DB06589,Pazopanib
,24643910,Km,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Km -Q1,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),μM,4.37,58792,DB06589,Pazopanib
,24643910,Vmax,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),[nM] / [·mg·min],15.34,58793,DB06589,Pazopanib
,24643910,Vmax,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),[nM] / [·mg·min],6.75,58794,DB06589,Pazopanib
,24643910,Vmax,"Likewise, Km values of OATP-1B3 for canertinib, nilotinib and vandetanib were 12.18±3.32, 7.84±1.43 and 4.37±0.79 μM, respectively, and Vmax values of OATP-1B3 for canertinib, nilotinib and vandetanib were 15.34±1.59, 6.75±0.42 and 194.64±10.58 nmol/mg protein per minute, respectively.",Role of OATP-1B1 and/or OATP-1B3 in hepatic disposition of tyrosine kinase inhibitors. ,Vmax-Q66,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24643910/),[nM] / [·mg·min],194.64,58795,DB06589,Pazopanib
,29680279,plasma-Cthrough levels,"Furthermore, the expected plasma-Cthrough levels (27.2 μg/mL) exceeds the defined therapeutic efficacy threshold of 20 μg/mL.",Solubility and bioavailability improvement of pazopanib hydrochloride. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29680279/),[μg] / [ml],27.2,60700,DB06589,Pazopanib
,26572909,fu%,We found that pazopanib was extensively bound in human plasma (>99.9 %) with a mean fu% value of 0.0106 ± 0.0013 % at 40 μg/mL.,Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26572909/),%,0.0106,72258,DB06589,Pazopanib
,26572909,fu%,"In isolated protein solutions, pazopanib at 40 μg/mL was mainly bound to albumin (40 g/L) and to a lesser extent to α1-acid glycoprotein (1 g/L) and low density lipoproteins (1.2 g/L), with a mean fu% of 0.0073 ± 0.0022 %, 0.992 ± 0.44 % and 7.4 ± 1.7 % respectively.",Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26572909/),%,0.0073,72259,DB06589,Pazopanib
,26572909,fu%,"In isolated protein solutions, pazopanib at 40 μg/mL was mainly bound to albumin (40 g/L) and to a lesser extent to α1-acid glycoprotein (1 g/L) and low density lipoproteins (1.2 g/L), with a mean fu% of 0.0073 ± 0.0022 %, 0.992 ± 0.44 % and 7.4 ± 1.7 % respectively.",Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26572909/),%,0.992,72260,DB06589,Pazopanib
,26572909,fu%,"In isolated protein solutions, pazopanib at 40 μg/mL was mainly bound to albumin (40 g/L) and to a lesser extent to α1-acid glycoprotein (1 g/L) and low density lipoproteins (1.2 g/L), with a mean fu% of 0.0073 ± 0.0022 %, 0.992 ± 0.44 % and 7.4 ± 1.7 % respectively.",Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26572909/),%,7.4,72261,DB06589,Pazopanib
,19509175,elimination half-life,The mean elimination half-life at this dose was 31.1 hours.,Phase I trial of pazopanib in patients with advanced cancer. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/19509175/),h,31.1,78061,DB06589,Pazopanib
>,19509175,trough concentration (C(24)),A mean target trough concentration (C(24)) >or=15 microg/mL (34 micromol/L) was achieved at 800 mg once daily.,Phase I trial of pazopanib in patients with advanced cancer. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19509175/),[μg] / [ml],15,78062,DB06589,Pazopanib
,28810837,plasmatic concentrations,"The mean (range) plasmatic concentrations of 400 and 600 pazopanib were respectively 283 (139-427) and 494 (227-761) μg.h/mL at Day 1, and 738 (487-989) and 1071 (678-1464) μg.h/mL at Day 15 i.e. higher than those previously reported with pazopanib, and were not directly influenced by bevacizumab infusion.",Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810837/),[h·μg] / [ml],283,78451,DB06589,Pazopanib
,28810837,plasmatic concentrations,"The mean (range) plasmatic concentrations of 400 and 600 pazopanib were respectively 283 (139-427) and 494 (227-761) μg.h/mL at Day 1, and 738 (487-989) and 1071 (678-1464) μg.h/mL at Day 15 i.e. higher than those previously reported with pazopanib, and were not directly influenced by bevacizumab infusion.",Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810837/),[h·μg] / [ml],494,78452,DB06589,Pazopanib
,28810837,plasmatic concentrations,"The mean (range) plasmatic concentrations of 400 and 600 pazopanib were respectively 283 (139-427) and 494 (227-761) μg.h/mL at Day 1, and 738 (487-989) and 1071 (678-1464) μg.h/mL at Day 15 i.e. higher than those previously reported with pazopanib, and were not directly influenced by bevacizumab infusion.",Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810837/),[h·μg] / [ml],738,78453,DB06589,Pazopanib
,28810837,plasmatic concentrations,"The mean (range) plasmatic concentrations of 400 and 600 pazopanib were respectively 283 (139-427) and 494 (227-761) μg.h/mL at Day 1, and 738 (487-989) and 1071 (678-1464) μg.h/mL at Day 15 i.e. higher than those previously reported with pazopanib, and were not directly influenced by bevacizumab infusion.",Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28810837/),[h·μg] / [ml],1071,78454,DB06589,Pazopanib
<,29051995,Cmin,"Sixty-one patients were included, of which 16.4% were underexposed (mean Cmin < 20 mg/L) using the 800 mg fixed-dosed schedule.",Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051995/),[mg] / [l],20,87565,DB06589,Pazopanib
>,29051995,Cmin,"In univariate analysis Cmin > 20 mg/L was related to longer progression free survival in renal cell cancer patients (34.1 vs. 12.5 weeks, n = 35, p = 0.027) and the overall population (25.0 vs. 8.8 weeks, n = 61, p = 0.012), but not in the sarcoma subgroup (18.7 vs. 8.8 weeks, n = 26, p = 0.142).",Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051995/),,20,87566,DB06589,Pazopanib
,29051995,Cmin,"In univariate analysis Cmin > 20 mg/L was related to longer progression free survival in renal cell cancer patients (34.1 vs. 12.5 weeks, n = 35, p = 0.027) and the overall population (25.0 vs. 8.8 weeks, n = 61, p = 0.012), but not in the sarcoma subgroup (18.7 vs. 8.8 weeks, n = 26, p = 0.142).",Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051995/),weeks,34.1,87567,DB06589,Pazopanib
,29051995,Cmin,"In univariate analysis Cmin > 20 mg/L was related to longer progression free survival in renal cell cancer patients (34.1 vs. 12.5 weeks, n = 35, p = 0.027) and the overall population (25.0 vs. 8.8 weeks, n = 61, p = 0.012), but not in the sarcoma subgroup (18.7 vs. 8.8 weeks, n = 26, p = 0.142).",Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051995/),weeks,25.0,87568,DB06589,Pazopanib
,29051995,Cmin,"In univariate analysis Cmin > 20 mg/L was related to longer progression free survival in renal cell cancer patients (34.1 vs. 12.5 weeks, n = 35, p = 0.027) and the overall population (25.0 vs. 8.8 weeks, n = 61, p = 0.012), but not in the sarcoma subgroup (18.7 vs. 8.8 weeks, n = 26, p = 0.142).",Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051995/),weeks,8.8,87569,DB06589,Pazopanib
,29051995,Cmin,"In univariate analysis Cmin > 20 mg/L was related to longer progression free survival in renal cell cancer patients (34.1 vs. 12.5 weeks, n = 35, p = 0.027) and the overall population (25.0 vs. 8.8 weeks, n = 61, p = 0.012), but not in the sarcoma subgroup (18.7 vs. 8.8 weeks, n = 26, p = 0.142).",Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051995/),weeks,18.7,87570,DB06589,Pazopanib
,29051995,progression free survival,"In univariate analysis Cmin > 20 mg/L was related to longer progression free survival in renal cell cancer patients (34.1 vs. 12.5 weeks, n = 35, p = 0.027) and the overall population (25.0 vs. 8.8 weeks, n = 61, p = 0.012), but not in the sarcoma subgroup (18.7 vs. 8.8 weeks, n = 26, p = 0.142).",Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051995/),weeks,34.1,87571,DB06589,Pazopanib
,29051995,progression free survival,"In univariate analysis Cmin > 20 mg/L was related to longer progression free survival in renal cell cancer patients (34.1 vs. 12.5 weeks, n = 35, p = 0.027) and the overall population (25.0 vs. 8.8 weeks, n = 61, p = 0.012), but not in the sarcoma subgroup (18.7 vs. 8.8 weeks, n = 26, p = 0.142).",Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051995/),weeks,12.5,87572,DB06589,Pazopanib
,29051995,progression free survival,"In univariate analysis Cmin > 20 mg/L was related to longer progression free survival in renal cell cancer patients (34.1 vs. 12.5 weeks, n = 35, p = 0.027) and the overall population (25.0 vs. 8.8 weeks, n = 61, p = 0.012), but not in the sarcoma subgroup (18.7 vs. 8.8 weeks, n = 26, p = 0.142).",Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051995/),weeks,25.0,87573,DB06589,Pazopanib
,29051995,progression free survival,"In univariate analysis Cmin > 20 mg/L was related to longer progression free survival in renal cell cancer patients (34.1 vs. 12.5 weeks, n = 35, p = 0.027) and the overall population (25.0 vs. 8.8 weeks, n = 61, p = 0.012), but not in the sarcoma subgroup (18.7 vs. 8.8 weeks, n = 26, p = 0.142).",Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051995/),weeks,8.8,87574,DB06589,Pazopanib
,29051995,progression free survival,"In univariate analysis Cmin > 20 mg/L was related to longer progression free survival in renal cell cancer patients (34.1 vs. 12.5 weeks, n = 35, p = 0.027) and the overall population (25.0 vs. 8.8 weeks, n = 61, p = 0.012), but not in the sarcoma subgroup (18.7 vs. 8.8 weeks, n = 26, p = 0.142).",Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051995/),weeks,18.7,87575,DB06589,Pazopanib
,29051995,hazard ratios,"In multivariate analysis Cmin > 20 mg/L was associated with hazard ratios of 0.25 (p = 0.021) in renal cancer, 0.12 (p = 0.011) in sarcoma and 0.38 (p = 0.017) in a pooled analysis.",Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051995/),,0,87576,DB06589,Pazopanib
>,29051995,Cmin,This study confirms that pazopanib Cmin > 20 mg/L relates to better progression free survival in renal cancer and points towards a similar trend in sarcoma patients.,Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29051995/),[mg] / [l],20,87577,DB06589,Pazopanib
≥,28185218,trough level,"Furthermore, a strong relationship between pazopanib trough level ≥20 mg/L and both tumor shrinkage and progression-free survival has been established.",Clinical Pharmacokinetics and Pharmacodynamics of Pazopanib: Towards Optimized Dosing. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28185218/),[mg] / [l],20,115836,DB06589,Pazopanib
,32020530,minimum plasma concentration (Cmin),"At the 800 mg QD dosing schedule, median minimum plasma concentration (Cmin), area under the concentration-time curve from 0 to 24 h (AUC0-24h), and maximum plasma concentration (Cmax) were 23.2 mg/L (interquartile range 18.5-27.6), 773 mg h/L (557-1009), and 40.6 mg/L (36.4-56.4) compared with 41.6 mg/L (30.5-55.8, p = 0.004), 942 mg h/L (885-1419, p = 0.027), and 50.2 mg/L (46.8-72.5, p = 0.074) at 400 mg twice daily.",Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients. ,Cmin-Q36,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32020530/),[mg] / [l],23.2,125787,DB06589,Pazopanib
,32020530,area under the concentration-time curve from 0 to 24 h (AUC0-24h),"At the 800 mg QD dosing schedule, median minimum plasma concentration (Cmin), area under the concentration-time curve from 0 to 24 h (AUC0-24h), and maximum plasma concentration (Cmax) were 23.2 mg/L (interquartile range 18.5-27.6), 773 mg h/L (557-1009), and 40.6 mg/L (36.4-56.4) compared with 41.6 mg/L (30.5-55.8, p = 0.004), 942 mg h/L (885-1419, p = 0.027), and 50.2 mg/L (46.8-72.5, p = 0.074) at 400 mg twice daily.",Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32020530/),[h·mg] / [l],773,125788,DB06589,Pazopanib
,32020530,maximum plasma concentration (Cmax),"At the 800 mg QD dosing schedule, median minimum plasma concentration (Cmin), area under the concentration-time curve from 0 to 24 h (AUC0-24h), and maximum plasma concentration (Cmax) were 23.2 mg/L (interquartile range 18.5-27.6), 773 mg h/L (557-1009), and 40.6 mg/L (36.4-56.4) compared with 41.6 mg/L (30.5-55.8, p = 0.004), 942 mg h/L (885-1419, p = 0.027), and 50.2 mg/L (46.8-72.5, p = 0.074) at 400 mg twice daily.",Cost-Neutral Optimization of Pazopanib Exposure by Splitting Intake Moments: A Prospective Pharmacokinetic Study in Cancer Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32020530/),[mg] / [l],40.6,125789,DB06589,Pazopanib
,30367352,clearance,Incorporation of CYP3A4*22 in the model resulted in a 35% lower clearance for variant carriers (0.18 vs. 0.27 L/h; difference in objective function value: - 9.7; p < 0.005).,Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30367352/),[l] / [h],0.18,134872,DB06589,Pazopanib
,30367352,clearance,Incorporation of CYP3A4*22 in the model resulted in a 35% lower clearance for variant carriers (0.18 vs. 0.27 L/h; difference in objective function value: - 9.7; p < 0.005).,Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30367352/),[l] / [h],0.27,134873,DB06589,Pazopanib
,30367352,trough concentrations,"Simulated median trough concentrations of cancer patients with CYP3A4*22 with 600 mg once daily or 800 mg once daily were 31 and 35 mg/L, respectively.",Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30367352/),[mg] / [l],31,134874,DB06589,Pazopanib
,30367352,trough concentrations,"Simulated median trough concentrations of cancer patients with CYP3A4*22 with 600 mg once daily or 800 mg once daily were 31 and 35 mg/L, respectively.",Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30367352/),[mg] / [l],35,134875,DB06589,Pazopanib
,30367352,trough concentrations,"The simulated trough concentrations for the population excluding the CYP3A4*22 carriers after 600 mg once daily or 800 mg once daily were 18 and 20 mg/L, respectively.",Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30367352/),[mg] / [l],18,134876,DB06589,Pazopanib
,30367352,trough concentrations,"The simulated trough concentrations for the population excluding the CYP3A4*22 carriers after 600 mg once daily or 800 mg once daily were 18 and 20 mg/L, respectively.",Impact of CYP3A4*22 on Pazopanib Pharmacokinetics in Cancer Patients. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30367352/),[mg] / [l],20,134877,DB06589,Pazopanib
,21831954,MTD,The MTD in patients with HCC (Child-Pugh class A) was 600 mg QD.,"Phase I dose-finding study of pazopanib in hepatocellular carcinoma: evaluation of early efficacy, pharmacokinetics, and pharmacodynamics. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21831954/),mg,600,159485,DB06589,Pazopanib
,23857966,MTD,The MTD was 450 mg/m(2) for tablet and 160 mg/m(2) for suspension.,Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23857966/),[mg] / [m(2],450,165546,DB06589,Pazopanib
,23857966,MTD,The MTD was 450 mg/m(2) for tablet and 160 mg/m(2) for suspension.,Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23857966/),[mg] / [m(2],160,165547,DB06589,Pazopanib
>,29330204,Ctrough,"Patients achieving early or late Ctrough >20.5 μg/mL had significantly longer DFS: not estimable (NE) versus 29.5 months, P = 0.006, and NE versus 29.9 months, P = 0.008, respectively.",Pazopanib Exposure Relationship with Clinical Efficacy and Safety in the Adjuvant Treatment of Advanced Renal Cell Carcinoma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29330204/),[μg] / [ml],20.5,168198,DB06589,Pazopanib
,23548165,absolute oral bioavailability,The absolute oral bioavailability of the 800 mg pazopanib tablet ranged from 14% to 39%.,"Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23548165/),%,14,179940,DB06589,Pazopanib
,23548165,absolute oral bioavailability,The absolute oral bioavailability of the 800 mg pazopanib tablet ranged from 14% to 39%.,"Bioavailability, metabolism and disposition of oral pazopanib in patients with advanced cancer. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23548165/),%,39,179941,DB06589,Pazopanib
,25072946,constant flow rate,"After liquid-liquid extraction with diethyl ether, pazopanib and gefitinib (internal standard) were separated using isocratic elution on an Ultrabase C18 column using a mobile phase consisting of a mixture in vol/vol proportion of 47:53 of ammonium acetate (pH, 7; 0.02 mol/L) and acetonitrile/methanol (70:30, vol/vol) pumped at a constant flow rate of 1 mL/min.",Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25072946/),[ml] / [min],1,189825,DB06589,Pazopanib
>,25072946,Recovery,Recovery of pazopanib from plasma was >80%.,Development and validation of an HPLC-UV method for pazopanib quantification in human plasma and application to patients with cancer in routine clinical practice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25072946/),%,80,189826,DB06589,Pazopanib
,31497882,objective response rate,The objective response rate was 31%; median PFS was 14.1 months (95% confidence interval [CI]: 7.1 and 22.2); and OS was 18.6 months (95% CI: 11.8 and 22.2).,"Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31497882/),%,31,196141,DB06589,Pazopanib
,31497882,PFS,The objective response rate was 31%; median PFS was 14.1 months (95% confidence interval [CI]: 7.1 and 22.2); and OS was 18.6 months (95% CI: 11.8 and 22.2).,"Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31497882/),month,14.1,196142,DB06589,Pazopanib
,31497882,OS,The objective response rate was 31%; median PFS was 14.1 months (95% confidence interval [CI]: 7.1 and 22.2); and OS was 18.6 months (95% CI: 11.8 and 22.2).,"Phase 1b trial of docetaxel, prednisone, and pazopanib in men with metastatic castration-resistant prostate cancer. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31497882/),month,18.6,196143,DB06589,Pazopanib
,27534647,lag time,"The absorption phase was modelled by two first-order processes: 36 % (relative standard error [RSE] 34 %) of the administered dose was absorbed with a relatively fast rate (0.4 h-1 [RSE 31 %]); after a lag time of 1.0 h (RSE 6 %), the remaining dose was absorbed at a slower rate (0.1 h-1 [RSE 28 %]).",Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27534647/),h,1.0,198989,DB06589,Pazopanib
,27534647,lag time,"The absorption phase was modelled by two first-order processes: 36 % (relative standard error [RSE] 34 %) of the administered dose was absorbed with a relatively fast rate (0.4 h-1 [RSE 31 %]); after a lag time of 1.0 h (RSE 6 %), the remaining dose was absorbed at a slower rate (0.1 h-1 [RSE 28 %]).",Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27534647/),1/[h],0.1,198990,DB06589,Pazopanib
,27534647,relative bioavailability (rF),The relative bioavailability (rF) at a dose of 200 mg was fixed to 1.,Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27534647/),,1,198991,DB06589,Pazopanib
,27534647,first-order decay constant,"Interestingly, the plasma exposure to pazopanib also decreased over time, modelled on rF with a maximum magnitude of 50 % (RSE 27 %) and a first-order decay constant of 0.15 day-1 (RSE 43 %).",Development of a Pharmacokinetic Model to Describe the Complex Pharmacokinetics of Pazopanib in Cancer Patients. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27534647/),1/[d],0.15,198992,DB06589,Pazopanib
,21811833,time to achieve maximum plasma concentration (T(max),"Administration of a single pazopanib 400 mg crushed tablet increased the area under the curve from 0 to 72 h (AUC((0-72)); 46%) and maximum observed plasma concentration (C(max); ~2-fold), and decreased time to achieve maximum plasma concentration (T(max); ~2 h), indicating increased rate and extent of oral absorption relative to whole-tablet administration.",A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21811833/),h,2,209253,DB06589,Pazopanib
,21811833,T(max),"Similarly, a single dose of pazopanib 400 mg suspension increased AUC((0-72)) (33%) and C(max) (29%), and decreased T(max) (1 h).",A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21811833/),h,1,209254,DB06589,Pazopanib
,25533184,MTD,"The MTD of D3w docetaxel was 50 mg/m(2), while for D1w MTD, it was 20 mg/m(2).",Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25533184/),[mg] / [m(2],50,213169,DB06589,Pazopanib
,25533184,MTD,"The MTD of D3w docetaxel was 50 mg/m(2), while for D1w MTD, it was 20 mg/m(2).",Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25533184/),mg,20,213170,DB06589,Pazopanib
,25533184,clearance,"In the D3w schedule, the administration of pazopanib led to a 33% lower docetaxel clearance (mean 31.5 vs 21.1 L/h/m(2); P = 0.019) and >50% increase in AUC(0-∞) (mean 1,602 vs 2,414 ng*h/mL; P = 0.029) compared with docetaxel single-agent data.",Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25533184/),[h·l] / [m(2],31.5,213171,DB06589,Pazopanib
,25533184,clearance,"In the D3w schedule, the administration of pazopanib led to a 33% lower docetaxel clearance (mean 31.5 vs 21.1 L/h/m(2); P = 0.019) and >50% increase in AUC(0-∞) (mean 1,602 vs 2,414 ng*h/mL; P = 0.029) compared with docetaxel single-agent data.",Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25533184/),[h·l] / [m(2],21.1,213172,DB06589,Pazopanib
,25533184,AUC(0-∞),"In the D3w schedule, the administration of pazopanib led to a 33% lower docetaxel clearance (mean 31.5 vs 21.1 L/h/m(2); P = 0.019) and >50% increase in AUC(0-∞) (mean 1,602 vs 2,414 ng*h/mL; P = 0.029) compared with docetaxel single-agent data.",Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25533184/),[h·ng] / [ml],"1,602",213173,DB06589,Pazopanib
,25533184,AUC(0-∞),"In the D3w schedule, the administration of pazopanib led to a 33% lower docetaxel clearance (mean 31.5 vs 21.1 L/h/m(2); P = 0.019) and >50% increase in AUC(0-∞) (mean 1,602 vs 2,414 ng*h/mL; P = 0.029) compared with docetaxel single-agent data.",Impact of pazopanib on docetaxel exposure: results of a phase I combination study with two different docetaxel schedules. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25533184/),[h·ng] / [ml],"2,414",213174,DB06589,Pazopanib
,29787262,oral bioavailability,"What's more, 6d possessed desirable pharmacokinetic profiles with the oral bioavailability of 72% in SD rats and considerable in vivo antitumor efficacy in a human colorectal adenocarcinoma (HT-29) xenograft model.",Discovery of Novel Pazopanib-Based HDAC and VEGFR Dual Inhibitors Targeting Cancer Epigenetics and Angiogenesis Simultaneously. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29787262/),%,72,231871,DB06589,Pazopanib
,24464355,trough concentration,"In all dose groups, the plasma concentrations after multiple doses of pazopanib exceeded the target trough concentration for inhibition of vascular endothelial growth factor receptor-2 activity (20 μg/mL).",Phase 1 study of pazopanib alone or combined with lapatinib in Japanese patients with solid tumors. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24464355/),[μg] / [ml],20,248071,DB06589,Pazopanib
,33010046,time-to-treatment discontinuation,"PK-guided dosing significantly increased median time-to-treatment discontinuation (252 vs 74 days, P = .012) with reduced toxicity and improved overall survival (not reached vs 313 days, P = .002) relative to conventional dosing in the control group.",Pharmacokinetically guided dosing has the potential to improve real-world outcomes of pazopanib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33010046/),d,252,266116,DB06589,Pazopanib
,33010046,time-to-treatment discontinuation,"PK-guided dosing significantly increased median time-to-treatment discontinuation (252 vs 74 days, P = .012) with reduced toxicity and improved overall survival (not reached vs 313 days, P = .002) relative to conventional dosing in the control group.",Pharmacokinetically guided dosing has the potential to improve real-world outcomes of pazopanib. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33010046/),d,74,266117,DB06589,Pazopanib
,24705975,apparent oral clearance (CL/F,"The apparent oral clearance (CL/F, mean value of 0.60 L/h) presented an inter-individual variability of 40 %, and an inter-occasion of 27 %.",Pharmacokinetics of pazopanib administered in combination with bevacizumab. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24705975/),[l] / [h],0.60,268345,DB06589,Pazopanib
,19365030,area under the curve from time 0 to the last quantifiable concentration,"A single oral dose of 4 or 100 mg/kg resulted in an area under the curve from time 0 to the last quantifiable concentration of 129.6 and 752.0 microg x h/mL, respectively.",Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19365030/),[h·μg] / [ml],129.6,268706,DB06589,Pazopanib
,19365030,area under the curve from time 0 to the last quantifiable concentration,"A single oral dose of 4 or 100 mg/kg resulted in an area under the curve from time 0 to the last quantifiable concentration of 129.6 and 752.0 microg x h/mL, respectively.",Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19365030/),[h·μg] / [ml],752.0,268707,DB06589,Pazopanib
